SITE015-0117

SITE015 (POL) › SITE015-0117

SITE015-0117

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2026-01-18

enrolled

AEs

7

Serious

0

Dropout signal

–

Adverse events

7

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-02 (study day 131); relationship: NOT RELATED

severe assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-27 (study day 126); relationship: NOT RELATED

mild assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-11-22 (study day 121); relationship: NOT RELATED

moderate assessed

Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 118); relationship: RELATED

severe assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 55); relationship: RELATED

moderate assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-18 (study day 25); relationship: NOT RELATED

mild assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 19); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.